Treatment is mainly supportive for STAT5B deficiency and HSCT can be curative in IPEX and CD25 deficiency, while gene-editing will hopefully be a definitive therapeutic option in the future. This evidence concerns the gene STAT5B and hyperinsulinemic hypoglycemia, familial, 4.